Leehey D J, Gollapudi P, Deakin A, Reid R W
Veterans Affairs Hospital, Hines, IL 60141.
J Lab Clin Med. 1991 Nov;118(5):484-91.
Endogenous opioids may be involved in the pathogenesis of ascites and edema in patients with liver cirrhosis. We administered the opioid antagonist naloxone (5 mg bolus followed by a 0.06 mg/min infusion) to eight male patients with alcoholic cirrhosis and ascites and to five healthy age- and sex-matched control subjects and determined the effects of naloxone on water and electrolyte excretion after a nonsustained water load (20 ml/kg). In comparison with saline vehicle infusion carried out in the same subjects, naloxone administration resulted in a 50% increase in urine output and creatinine clearance and twofold increases in sodium and potassium excretion in patients with cirrhosis. Fractional sodium and potassium excretion, minimal urinary osmolality, plasma vasopressin and aldosterone levels, arterial blood pressure, and heart rate were not affected by naloxone treatment. The diuretic effect of naloxone was not observed in control subjects. Plasma naloxone levels were about six times higher in patients with cirrhosis than in control subjects (probably because of impaired metabolism of the drug) but only a weak correlation was found between drug levels and the degree of diuresis observed. The diuretic effect of naloxone may be related to an increase in glomerular filtration rate, possibly in conjunction with altered tubular reabsorption.
内源性阿片类物质可能参与肝硬化患者腹水和水肿的发病机制。我们对8名患有酒精性肝硬化和腹水的男性患者以及5名年龄和性别匹配的健康对照受试者给予阿片类拮抗剂纳洛酮(静脉推注5毫克,随后以0.06毫克/分钟的速度输注),并在给予非持续性水负荷(20毫升/千克)后测定纳洛酮对水和电解质排泄的影响。与在相同受试者中输注生理盐水相比,给予纳洛酮后,肝硬化患者的尿量和肌酐清除率增加了50%,钠和钾排泄增加了两倍。纳洛酮治疗对钠和钾的排泄分数、最低尿渗透压、血浆血管加压素和醛固酮水平、动脉血压及心率均无影响。在对照受试者中未观察到纳洛酮的利尿作用。肝硬化患者的血浆纳洛酮水平比对照受试者高约6倍(可能是由于药物代谢受损),但药物水平与观察到的利尿程度之间仅发现弱相关性。纳洛酮的利尿作用可能与肾小球滤过率增加有关,可能还伴有肾小管重吸收改变。